Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that typically begins in childhood and is characterized by inattention and/or hyperactivity-impulsivity. Attention-deficit/hyperactivity disorder affects 5% of children and adolescents¹ and 2.5% of adults worldwide² and is frequently associated with other disorders, such as neurodevelopmental disorders, borderline personality, conduct or mood disorders, and psychotic disorders (PDs).

In this systematic review and meta-analysis, we evaluated the association between Attention-Deficit/Deficit Hyperactivity (ADHD) and atypical Sensory Processing Patterns (SPPs). We searched PubMed, Embase, and Web of Science from their inception until June 30^th, 2024. We included studies examining SPP using questionnaires in participants with a diagnosis of ADHD compared with healthy controls. The study risk of bias was assessed using a modified Newcastle-Ottawa Scale. A random-effects meta-analysis was conducted using R software (Version 4.3.1), considering sensory modulation atypicities severity as the primary outcome. We explored the risk of publication bias and conducted sensitivity analyses to test the robustness of the findings. After screening 10,750 references, we included 30 studies (reported in 32 publications) encompassing a total of 5,374 participants, with 23 studies focusing on children, and seven on adults. Patients with ADHD presented significantly more severe sensory atypicities than the control group in multiple domains: sensory sensitivity (k=13; SMD=1.17; 5% CI [0.75;1.59]; I²=87%), sensory avoiding (k=11; SMD=1.15; 95% CI [0.66;1.64]; I²=92%), low sensory registration (k=23; SMD=1.22; 95%CI [0.89;1.56]; I²=92%), and sensory seeking (k=15; SMD=1.23; 95%CI [0.48;1.97]; I²=97%). Heterogeneity was high in all analyses. Only nine studies were deemed at overall low risk of bias. Even though available ADHD clinical guidelines do not specifically mention the need to assess sensory processing in ADHD, our meta-analysis suggests that this should be systematically explored in the evaluation of children and adults referred for ADHD.

The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet, findings are inconsistent regarding negative symptoms, while other dimensions such as disorganization, depression, and excitement, have not been investigated. In addition, meta-analyses use aggregated data discarding important confounding variables which is a source of bias. PubMed, ScienceDirect and PsycINFO were used to search for publications from inception to September 27, 2022. We contacted the authors of relevant studies to extract raw datasets and perform an Individual Participant Data meta-analysis (IPDMA). Inclusion criteria were: psychopathology of individuals with schizophrenia spectrum disorders assessed by the Positive and Negative Syndrome Scale (PANSS); cannabis-users had to either have a diagnosis of cannabis use disorder or use cannabis at least twice a week. The main outcomes were the PANSS subscores extracted via the 3-factor (positive, negative and general) and 5-factor (positive, negative, disorganization, depression, excitement) structures. Preregistration is accessible via Prospero: ID CRD42022329172. Among the 1149 identified studies, 65 were eligible and 21 datasets were shared, totaling 3677 IPD and 3053 complete cases. The adjusted multivariate analysis revealed that relative to non-use, cannabis use was associated with higher severity of positive dimension (3-factor: Adjusted Mean Difference, aMD = 0.34, 95% Confidence Interval, CI = [0.03; 0.66]; 5-factor: aMD = 0.38, 95% CI = [0.08; 0.63]), lower severity of negative dimension (3-factor: aMD = −0.49, 95% CI [−0.90; −0.09]; 5-factor: aMD = −0.50, 95% CI = [−0.91; −0.08]), higher severity of excitement dimension (aMD = 0.16, 95% CI = [0.03; 0.28]). No association was found between cannabis use and disorganization (aMD = −0.13, 95% CI = [−0.42; 0.17]) or depression (aMD = −0.14, 95% CI = [−0.34; 0.06]). No causal relationship can be inferred from the current results. The findings could be in favor of both a detrimental and beneficial effect of cannabis on positive and negative symptoms, respectively. Longitudinal designs are needed to understand the role of cannabis is this association. The reported effect sizes are small and CIs are wide, the interpretation of findings should be taken with caution. This research did not receive any specific grant or funding. Primary financial support for authors was provided by Le Vinatier Psychiatric Hospital.

We conducted an umbrella review of systematic reviews (SRs) - with or without meta-analysis (MA) - of randomized controlled trials (RCTs) assessing non-pharmacological sleep interventions for children and adolescents across various clinical populations. We searched multiple electronic databases up to 24/01/24. Meta-analyzable data from RCTs in the retrieved SRs/MAs were pooled using Metaumbrella. Primary outcomes were subjective/objective child sleep parameters. Additional outcomes included child health/functioning and parental sleep/health. The quality of the MAs/SRs was assessed with AMSTAR-2, and the certainty of evidence using GRADE. We included 93 SRs/MAs covering 393 RCTs, with 25 (17%, 39% and 30%: high, moderate, and low quality) providing data for quantitative synthesis. Behavioral interventions, usually multicomponent including parent training, psychoeducation, and/or specific sleep therapy/strategies, showed beneficial effects on night waking, sleep duration, overall sleep disturbance, mood/depression, and maternal sleep quality (standardized mean difference [SMD]: 0.10 to 0.80) in participants with sleep problems without a formal sleep disorder diagnosis. For those with a formal diagnosis (mainly insomnia), benefits were found for night waking, sleep efficiency (subjective/actigraphically measured), and sleep onset latency (mean SMD: 0.49 to 0.97). Those with ADHD improved in bedtime resistance, night waking, parasomnias, sleep anxiety, ADHD symptoms, sleep disturbance, and quality of life (mean SMD: 0.18 to 0.49). For those with autism, sleep disturbance improved (mean SMD: 0.70). However, all findings were of low to very low certainty of evidence. Among non-pharmacological interventions for sleep difficulties in youth, only behavioral interventions are supported by meta-analytic evidence, yet with small to moderate effect sizes and limited certainty of evidence.

Concerns have been raised about early vs. later impacts of the COVID-19 pandemic on suicidal behavior. However, data remain sparse to date. We investigated all calls for intentional drug or other toxic ingestions to the eight Poison Control Centers in France between 1st January 2018 and 31st May 2022. Data were extracted from the French National Database of Poisonings. Calls during the study period were analyzed using time trends and time series analyses with SARIMA models (based on the first two years). Breakpoints were determined using Chow test. These analyses were performed together with examination of age groups (≤ 11, 12–24, 25–64, ≥ 65 years) and gender effects when possible. Over the studied period, 66,589 calls for suicide attempts were received. Overall, there was a downward trend from 2018, which slowed down in October 2019 and was followed by an increase from November 2020. Number of calls observed during the COVID period were above what was expected. However, important differences were found according to age and gender. The increase in calls from mid-2020 was particularly observed in young females, while middle-aged adults showed a persisting decrease. An increase in older-aged people was observed from mid-2019 and persisted during the pandemic. The pandemic may therefore have exacerbated a pre-existing fragile situation in adolescents and old-aged people. This study emphasizes the rapidly evolving situation regarding suicidal behaviour during the pandemic, the possibility of age and gender differences in impact, and the value of having access to real-time information to monitor suicidal acts.